Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Mackensen

Showing results (141-150 of 196) with videos related to

Pageof 20
Sort By:
Oncoimmunology|September 20, 2018
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsTodd A Braciak, Claudia C Roskopf, Sarah Wildenhain, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton, Marco Gerlinger, Olga de la Rosa, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 26, 2017
Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13Yazid J Resheq, Ann-Katrin Menzner, Jacobus Bosch, et al.
Nature Medicine|April 17, 2025
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsFabian Müller, Andreas Wirsching, Melanie Hagen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid CancersLena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, et al.
Cytotherapy|November 12, 2024
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disordersDimitrios Mougiakakos, Ranjita Sengupta, Ralf Gold, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
The Journal of Clinical Investigation|January 30, 2018
BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host diseaseEvelyn Ullrich, Benjamin Abendroth, Johanna Rothamer, et al.
European Journal of Immunology|March 30, 2021
Upregulation of CCR4 in activated CD8<sup>+</sup> T cells indicates enhanced lung homing in patients with severe acute SARS-CoV-2 infectionSilvia Spoerl, Anita N Kremer, Michael Aigner, et al.
Pageof 20

Showing results (141-150 of 196) with videos related to

Sort By:
Pageof 20
Oncoimmunology|September 20, 2018
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsTodd A Braciak, Claudia C Roskopf, Sarah Wildenhain, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton, Marco Gerlinger, Olga de la Rosa, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 26, 2017
Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13Yazid J Resheq, Ann-Katrin Menzner, Jacobus Bosch, et al.
Nature Medicine|April 17, 2025
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsFabian Müller, Andreas Wirsching, Melanie Hagen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid CancersLena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, et al.
Cytotherapy|November 12, 2024
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disordersDimitrios Mougiakakos, Ranjita Sengupta, Ralf Gold, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
The Journal of Clinical Investigation|January 30, 2018
BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host diseaseEvelyn Ullrich, Benjamin Abendroth, Johanna Rothamer, et al.
European Journal of Immunology|March 30, 2021
Upregulation of CCR4 in activated CD8<sup>+</sup> T cells indicates enhanced lung homing in patients with severe acute SARS-CoV-2 infectionSilvia Spoerl, Anita N Kremer, Michael Aigner, et al.
Pageof 20